Therapeutic Efficacy of Artemether-Lumefantrine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Metehara Town, Central-East Ethiopia
| dc.contributor.advisor | Hassen Mamo | |
| dc.contributor.advisor | Ashenafi Assefa | |
| dc.contributor.author | Mahelet Tesfaye | |
| dc.date.accessioned | 2025-08-18T00:56:34Z | |
| dc.date.available | 2025-08-18T00:56:34Z | |
| dc.date.issued | 2024-03 | |
| dc.description.abstract | Monitoring and identification of drug-resistant Plasmodium falciparum strains is paramount for the fight against malaria. Close surveillance of the emergence and distribution of artemisinin resistance is recommended to guide policy decisions. The efficacy of national first- and second-line anti-malarial treatments should be monitored at least once every 2 years, as recommended in the WHO standard protocol. In Ethiopia, a three-day regime of AL (artemether 20mg and lumefantrine 120mg in each tablet) is the first-line anti-malarial drug for the treatment of uncomplicated P. falciparum malaria since 2004. The objective of this study was assessing the therapeutic efficacy of AL for the treatment of uncomplicated P. falciparum malaria in Metehara, central-east Ethiopia. The study was conducted at Metehara town health center from November 26, 2020 to March 24, 2021. One-arm prospective evaluation was conducted on the clinical and parasitological responses to directly observed treatment for uncomplicated P. falciparum malaria. During the study regime, 80 patients were screened and 73(50 male and 30 female) participants completed the follow-up and among those 14 patients were <5 age, 25 between the age 5-14 and 34 were >14. The overall cure rate was 100% (73/73; 95% CI: 95.1-100.0) with no early treatment failure, late treatment failure, and late parasitological failure as in Kaplan–Meier analyses all participants completely recovered from parasitemia and fever on day (D) 3; the asexual parasite clearance rate was 100% and clinical symptoms resolved quickly. Gametocyte carriage was reduced from 8.4% on D0 to 1% on D3 and complete clearance was achieved on D7. There was no serious adverse event. In the study location, AL was effective for treating uncomplicated P. falciparum malaria. | |
| dc.identifier.uri | https://etd.aau.edu.et/handle/123456789/7007 | |
| dc.language.iso | en_US | |
| dc.publisher | Addis Ababa University | |
| dc.subject | Artemether-Lumefantrine | |
| dc.subject | P. Falciparum | |
| dc.subject | Therapeutic Efficacy | |
| dc.subject | Metehara | |
| dc.title | Therapeutic Efficacy of Artemether-Lumefantrine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Metehara Town, Central-East Ethiopia | |
| dc.type | Thesis |